|
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
|
DB01640 |
|
|
Ferrous tartrate
|
DB13639 |
|
|
Eltanolone
|
DB12308 |
[Eltanolone is under investigation in clinical trial NCT02603926 (Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone).] |
|
GI-181771X
|
DB12309 |
[Gski181771 X is under investigation in clinical trial NCT00600743 (Effect of a CCK-1R Agonist on Food Intake in Humans).] |
|
Entolimod
|
DB12304 |
[Entolimod has been used in trials studying the treatment of Mucositis, Tongue Cancer, Colorectal Cancer, Stage IVA Verrucous Carcinoma of the Larynx, and Stage IVB Verrucous Carcinoma of the Larynx, among others.] |
|
Tiracizine
|
DB13635 |
|
|
Margetuximab
|
DB14967 |
[Margetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program).] |
|
Venglustat
|
DB14966 |
[Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).] |
|
Etanautine
|
DB13636 |
|
|
Dasotraline
|
DB12305 |
[Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.] |
|
GTX-758
|
DB14969 |
[GTX-758 is under investigation in clinical trial NCT01420861 (GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer).] |
|
Cipargamin
|
DB12306 |
[Cipargamin has been used in trials studying the treatment of Malaria, Cure Rate, and Plasmodium Falciparum Malaria.] |
|
Tenitramine
|
DB13637 |
|
|
Cefbuperazone
|
DB13638 |
|
|
Foretinib
|
DB12307 |
[Foretinib has been used in trials studying the treatment of Cancer, Breast Cancer, Carcinoma, Renal Cell, Recurrent Breast Cancer, and Neoplasms, Head and Neck, among others. Foretinib is an orally available small molecule compound designed to target multiple RTKs implicated in the development, progression and spread of cancer. It inhibits the activation of MET, RON, ERK and AKT, decreased proliferation and increased apoptosis.] |
|
Bacillus calmette-guerin substrain tokyo 172-1 live antigen
|
DB14968 |
[Bacillus calmette-guerin substrain tokyo 172-1 live antigen is under investigation in clinical trial NCT03091660 (S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer).] |
|
Methoserpidine
|
DB13631 |
|
|
P-nitrobiphenyl
|
DB12300 |
[Pnb has been used in trials studying the treatment of Pelvic Organ Prolapse.] |
|
Konjac mannan
|
DB14963 |
[Konjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).] |
|
Trastuzumab deruxtecan
|
DB14962 |
[Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer.[L10842] It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguish it from other members of its class.[A188988] Trastuzumab deruxtecan has been granted FDA approval for specific patients with HER-2 positive breast cancer who have failed other treatments.[L10842]
Promising results from a clinical trial prompted accelerated FDA approval for this indication on December 20, 2019.[L10845] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca. The continued approval of this drug will depend on the confirmation of its beneficial effects in ongoing clinical trials.[L10842]] |
